Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial

Abstract

Decreases in serum and urine concentrations of markers of inflammation occurred as early as 24 h after treatment with golimumab, and most of these improvements were sustained through week 24 in group 1.

Manipulation of the hepcidin pathway for therapeutic purposes

“…83,84 Anti-TNFα antibody in patients with rheumatoid arthritis similarly caused a sustained decrease in hepcidin. 85 Although TNFα by itself suppresses hepcidin in vitro, 31 the observed opposite effects of the anti-TNFα treatment in patients are likely a consequence of a general decrease in inflammation and IL-6 levels. Treatment with a small molecule STAT3 inhibitor (AG490) also decreased hepcidin and increased serum iron in healthy mice.…”

Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis

“…Because IL-6 and other cytokines are critically involved in the pathogenesis of ACD, biologic therapies such as TCZ and TNF inhibitors could potentially increase hemoglobin (Hb) levels after treatment. Indeed, increase of Hb levels after biologic therapies has been demonstrated in RA and in other inflammatory diseases [5] [7] [8] [9] [10] [11] [12].…”

Role of Matrix Metalloproteinase 3 in Predicting the Efficiency of Therapy for Early Rheumatoid Arthritis: The Remarca Trial

“…Клинико-лабораторные показатели в группах пациентов в зависимости от уровня ММП3 в сыворотке крови, Me [25- [27,28]. Оценка уровня ММП3 может быть полезна для мо-ниторирования эффективности терапии и решения вопро-са о дальнейшей тактике лечения.…”

“…В ряде иссле-дований продемонстрировано снижение сывороточной концентрации данного маркера у больных РА с хорошим эффектом БПВП и ГИБП [24][25][26][27][28]. В нашей работе мы про-анализировали роль ММП3 в качестве предиктора эффек-тивности терапии раннего РА.…”